

Pharmaceutical Management Agency

# Section H Update for Hospital Pharmaceuticals

Effective 1 June 2017

Cumulative for April, May and June 2017



## **Contents**

Summary of decisions effective 1 June 2017 .....	3
Section H changes to Part II .....	4
Index .....	12

## Summary of decisions

EFFECTIVE 1 JUNE 2017

- Alfacalcidol (One-Alpha) cap 0.25 mcg and 1 mcg – addition of HSS
- Alfacalcidol (One-Alpha) oral drops 2 mcg per ml – new listing and addition of HSS
- Amoxicillin with clavulanic acid (Curam) grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml – brand change and addition of HSS
- Amoxicillin with clavulanic acid (Augmentin) grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml – to be delisted 1 August 2017
- Aminolevulinic acid hydrochloride (Gliolan) powder for oral soln, 30 mg per ml, 1.5 g vial – new listing
- Celecoxib (Celecoxib Pfizer) cap 100 mg and 200 mg – new listing and addition of HSS
- Celecoxib cap 400 mg – to be delisted 1 August 2017
- Dimethicone (healthE Dimethicone 4% Lotion) lotn 4%, 200 ml – amended Therapeutic subgroup
- Influenza vaccine (Influvac) inj 45 mcg in 0.5 ml syringe – HSS removed
- Morphine tartrate (Hospira) inj 80 mg per ml, 5 ml ampoule – to be delisted 1 August 2017
- Nifedipine (Adalat 10) tab long-acting 10 mg – new listing and addition of HSS
- Nystatin (Nilstat) vaginal crm 100,000 u per 5 g with applicator(s), 75 g – new listing and addition of HSS
- Pegylated interferon alfa-2a (Pegasys RBV Combination Pack) inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) – to be delisted 1 August 2017
- Peptide-based enteral feed 1.5 kcal/ml (Vital) liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle – amended chemical name
- Pyridoxine hydrochloride inj 100 mg per ml, 30 ml vial – new listing
- Sulphadiazine silver (Flamazine) crm 1%, 50 g – price decrease and addition of HSS
- Temozolomide (Orion Temozolomide) cap 5 mg, 20 mg, 100 mg and 250 mg – amended restriction
- Testosterone (Androderm) patch 5 mg per day – new listing

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

## Section H changes to Part II

Effective 1 June 2017

### ALIMENTARY TRACT AND METABOLISM

27	ALFACALCIDOL (addition of HSS) Cap 0.25 mcg – 1% DV Aug-17 to 2020 .....	26.32	100	<b>One-Alpha</b>
	Cap 1 mcg – 1% DV Aug-17 to 2020 .....	87.98	100	<b>One-Alpha</b>
27	ALFACALCIDOL (new listing) Oral drops 2 mcg per ml – 1% DV Aug-17 to 2020 .....	60.68	20 ml	<b>One-Alpha</b>
27	PYRIDOXINE HYDROCHLORIDE (new listing) Inj 100 mg per ml, 30 ml vial			

### CARDIOVASCULAR SYSTEM

46	NIFEDIPINE (new listing and addition of HSS) Tab long-acting 10 mg – 1% DV Aug-17 to 2020 .....	10.63	60	<b>Adalat 10</b>
----	--	-------	----	------------------

### DERMATOLOGICALS

54	SULPHADIAZINE SILVER (↓ price and addition of HSS) Crm 1% – 1% DV Aug-17 to 2020 .....	10.80	50 g	<b>Flamazine</b>
55	<del>Antiparasitics Barrier Creams</del> (amended Therapeutic subgroup) DIMETHICONE Lotn 4% – 1% DV Jul-17 to 2019 .....	4.98	200 ml	<b>healthE Dimethicone 4% Lotion</b>

### GENITO-URINARY SYSTEM

60	NYSTATIN (new listing and addition of HSS) Vaginal crm 100,000 u per 5 g with applicator(s) – 1% DV Aug-17 to 2020 .....	4.45	75 g	<b>Nilstat</b>
----	--	------	------	----------------

### HORMONE PREPARATIONS

65	TESTOSTERONE (new listing) Patch 5 mg per day .....	80.00	30	<b>Androderm</b>
----	--	-------	----	------------------

### INFECTIONS

78	AMOXICILLIN WITH CLAVULANIC ACID (brand change) Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml – 1% DV Aug-17 to 2019 .....	2.20	100 ml	<b>Curam</b>
	Note – Augmentin grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml to be delisted from 1 August 2017.			

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

### Changes to Section H Part II – effective 1 June 2017 (continued)

97	PEGYLATED INTERFERON ALFA-2A (delisting) → Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) .....	1,159.84	1	Pegasys RBV Combination Pack
----	--	----------	---	---------------------------------

Note – Pegasys RBV Combination Pack inj 180 mcg prefilled syringe (4) with ribavirin tab 200 ng (112) to be delisted from 1 August 2017.

### MUSCULOSKELETAL SYSTEM

107	CELECOXIB (new listing and addition of HSS) → Cap 100 mg – 1% DV Aug-17 to 2020.....	3.63	60	<b>Celecoxib Pfizer</b>
	→ Cap 200 mg – 1% DV Aug-17 to 2020.....	2.30	30	<b>Celecoxib Pfizer</b>

Note – The DV limit of 1% applies to the celecoxib chemical rather than each individual line item.  
Note – Celecoxib cap 400 mg to be delisted from 1 August 2017.

### NERVOUS SYSTEM

115	MORPHINE TARTRATE (delisting) Inj 80 mg per ml, 5 ml ampoule .....	107.67	5	Hospira
-----	---	--------	---	---------

Note – Hospira inj 80 mg per ml, 5 ml ampoule to be delisted from 1 August 2017.

### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

140	TEMOZOLOMIDE (amended restriction) → Cap 5 mg – 1% DV Feb-17 to 2019.....	10.20	5	<b>Orion Temozolomide</b>
	→ Cap 20 mg – 1% DV Feb-17 to 2019.....	18.30	5	<b>Orion Temozolomide</b>
	→ Cap 100 mg – 1% DV Feb-17 to 2019.....	40.20	5	<b>Orion Temozolomide</b>
	→ Cap 250 mg – 1% DV Feb-17 to 2019.....	96.80	5	<b>Orion Temozolomide</b>

#### Restricted

##### Initiation — High grade gliomas

*Re-assessment required after 12 months*

All of the following:

1 Either:

1.1 Patient has newly diagnosed glioblastoma multiforme; or

1.2 Patient has newly diagnosed anaplastic astrocytoma\*; and

2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and

3 Following concomitant treatment temozolomide is to be used for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m<sup>2</sup> per day.

##### Initiation — Neuroendocrine tumours

*Re-assessment required after 9 months*

All of the following:

1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour\*; and

2 Temozolomide is to be given in combination with capecitabine; and

3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m<sup>2</sup> per day; and

4 Temozolomide to be discontinued at disease progression.

##### Continuation — High grade gliomas

*Re-assessment required after 12 months*

Either:

1 Both:

*continued...*

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 June 2017 (continued)**

*continued...*

- 1.1 Patient has glioblastoma multiforme; and
- 1.2 The treatment remains appropriate and the patient is benefitting from treatment; or
- 2 All of the following:
  - 2.1 Patient has anaplastic astrocytoma\*; and
  - 2.2 The treatment remains appropriate and the patient is benefitting from treatment; and
  - 2.3 Adjuvant temozolomide is to be used for a maximum of 24 months.

Continuation — Neuroendocrine tumours

Re-assessment required after 6 months

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indication marked with a \* is an Unapproved Indication. Temozolomide is not funded for the treatment of relapsed glioblastoma multiforme **high grade glioma**.

147	AMINOLEVULINIC ACID HYDROCHLORIDE (new listing)			
	→ Powder for oral soln, 30 mg per ml, 1.5 g vial .....	4,400.00	1	Giolan
		44,000.00	10	Giolan

Restricted

Initiation – high grade malignant glioma

All of the following:

- 1 Patient has newly diagnosed, untreated, glioblastoma multiforme; and
- 2 Treatment to be used as adjuvant to fluorescence-guided resection; and
- 3 Patient's tumour is amenable to complete resection.

**SPECIAL FOODS**

216	PEPTIDE-BASED ORAL <b>ENTERAL FEED 1.5 KCAL/ML</b> (amended chemical name)			
	→ Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per			
	100 ml, bottle .....	18.06	1,000 ml	Vital

**VACCINES**

229	INFLUENZA VACCINE (HSS expired)			
	→ Inj 45 mcg in 0.5 ml syringe			
	– <del>0% DV Feb-17 to 31 Dec 2019</del> <b>31 May 2017</b> .....	90.00	10	Influvac

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 May 2017

### DERMATOLOGICALS

55	DIMETHICONE (new listing and addition of HSS) Lotn 4% - <b>1% DV Jul-17 to 2019</b> .....	4.98	200 ml	<b>healthE Dimethicone 4% Lotion</b>
58	CALCIPOTRIOL (addition of HSS) Oint 50 mcg per g – <b>1% DV Jul-17 to 2020</b> .....	45.00	100 g	<b>Daivonex</b>

### HORMONE PREPARATIONS

66	DEXAMETHASONE PHOSPHATE (new pack size) Inj 4 mg per ml, 2 ml ampoule – <b>1% DV Jul-16 to 2019</b> .....	25.18	10	<b>Max Health</b>
Note – This is a listing of a new pack size				

### INFECTIONS

78	PIPERACILLIN WITH TAZOBACTAM (new listing) → Inj 4 g with tazobactam 0.5 g vial .....	15.50	1	Tazocin EF
86	METRONIDAZOLE (new listing) Inj 5 mg per ml, 100 ml bottle.....	1.39	1	AFT

### NERVOUS SYSTEM

128	FLUPHENAZINE DECANOATE – Restricted: For continuation only (delisting) → Inj 12.5 mg per 0.5 ml ampoule .....	17.60	5	Modecate
	→ Inj 25 mg per ml, 1 ml ampoule.....	27.90	5	Modecate
	→ Inj 25 mg per ml, 2 ml ampoule.....			<i>e.g. Modecate</i>
	→ Inj 100 mg per ml, 1 ml ampoule.....	154.50	5	Modecate
Note – Modecate inj 12.5 mg per 0.5 ml, inj 25 mg per ml, 1 ml and 2 ml, and 100 mg per ml, 1 ml ampoules to be delisted from 1 December 2017.				

### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

184	AZATHIOPRINE (brand change) Tab 25 mg – <b>1% DV Jul-17 to 2019</b> .....	9.66	100	<b>Imuran</b>
	Tab 50 mg – <b>1% DV Jul-17 to 2019</b> .....	10.58	100	<b>Imuran</b>
Note – Azamun tab 25 mg and 50 mg to be delisted from 1 July 2017.				

### RESPIRATORY SYSTEM AND ALLERGIES

191	SODIUM CROMOGLYCATE (delisting) Powder for inhalation 20 mg per dose Note – Sodium cromoglycate powder for inhalation 20 mg per dose to be delisted from 1 June 2017.			
-----	---	--	--	--

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 May 2017 (continued)**

**VACCINES**

229 INFLUENZA VACCINE (Restriction amended (affected criterion only shown))

→ Inj 45 mcg in 0.5 ml syringe

– 0% DV Feb-17 to 31 Dec 2019 ..... 90.00 10 **Influvac**

Restricted

Initiation — Other conditions

**Any of the following Either:**

1 Any of the following:

- 1.1 Diabetes; or
- 1.2 chronic renal disease; or
- 1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
- 1.4 Autoimmune disease; or
- 1.5 Immune suppression or immune deficiency; or
- 1.6 HIV; or
- 1.7 Transplant recipient; or
- 1.8 Neuromuscular and CNS diseases/ disorders; or
- 1.9 Haemoglobinopathies; or
- 1.10 Is a child on long term aspirin; or
- 1.11 Has a cochlear implant; or
- 1.12 Errors of metabolism at risk of major metabolic decompensation; or
- 1.13 Pre and post splenectomy; or
- 1.14 Down syndrome; or
- 1.15 Is pregnant; or
- 1.16 Is a child aged four and under who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or

2 Patients who are compulsorily detained long-term in a forensic unit within a DHB hospital; or

**3 People under 18 years of age living within the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board).**



		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	--	-------------------------------------

## Changes to Section H Part II – effective 1 April 2017

### BLOOD AND BLOOD FORMING ORGANS

40	SODIUM CHLORIDE (new listing) Inj 0.9%, 20 ml ampoule.....	5.00	20	Multichem
40	SODIUM CHLORIDE (HSS suspended) Inj 0.9%, 20 ml ampoule – <b>1% DV Mar-17 to 2019</b> <b>31 Mar 2017</b> .....	7.50	30	InterPharma
40	WATER (new listing) Inj 20 ml ampoule.....	5.00	20	Multichem
40	WATER (HSS suspended) Inj 20 ml ampoule – <b>1% DV Mar-17 to 2019-31 Mar 2017</b> .....	7.50	30	Interpharma

### CARDIOVASCULAR SYSTEM

44	AMIODARONE HYDROCHLORIDE (brand change) Inj 50 mg per ml, 3 ml ampoule – <b>1% DV Jun-17 to 2019</b> .....	9.98	5	<b>Lodi</b>
	Note – Cordarone-X inj 50 mg per ml, 3 ml ampule to be delisted from 1 June 2017.			

### GENITO-URINARY SYSTEM

61	LEVONORGESTREL (↑ price and addition of HSS) Tab 1.5 mg – <b>1% DV Jun-17 to 2019</b> .....	4.95	1	<b>Postinor-1</b>
----	--	------	---	-------------------

### HORMONE PREPARATIONS

67	PREDNISONE (addition of HSS) Tab 1 mg – <b>1% DV Jun-17 to 2020</b> .....	10.68	500	<b>Apo-Prednisone</b>
	Tab 2.5 mg – <b>1% DV Jun-17 to 2020</b> .....	12.09	500	<b>Apo-Prednisone</b>
	Tab 5 mg – <b>1% DV Jun-17 to 2020</b> .....	11.09	500	<b>Apo-Prednisone</b>
	Tab 20 mg – <b>1% DV Jun-17 to 2020</b> .....	29.03	500	<b>Apo-Prednisone</b>
68	CLOMIFENE GLOMIPHENE CITRATE (chemical name change) Tab 50 mg .....	29.84	10	Mylan Clomiphene Serophene

### INFECTIONS

81	FUSIDIC ACID (addition of HSS) → Tab 250 mg – <b>1% DV Jun-17 to 2020</b> .....	34.50	12	<b>Fucidin</b>
90	DARUNAVIR (↓ price and addition of HSS) → Tab 400 mg – <b>1% DV Jun-17 to 2020</b> .....	335.00	60	<b>Prezista</b>
	→ Tab 600 mg – <b>1% DV Jun-17 to 2020</b> .....	476.00	60	<b>Prezista</b>

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 April 2017 (continued)

### MUSCULOSKELETAL SYSTEM

99	AURANOFIN - <b>Restricted: for continuation only</b> (restriction added and delisting) Tab 3 mg Note – Auranofin tab 3 mg to be delisted from 1 September 2017.			
99	LEFLUNOMIDE (brand change) Tab 10 mg – <b>1% DV Jun-17 to 2020</b> .....	2.90	30	<b>Apo-Leflunomide</b>
	Tab 20 mg – <b>1% DV Jun-17 to 2020</b> .....	2.90	30	<b>Apo-Leflunomide</b>
	Note – Arava tab 10 mg and 20 mg to be delisted from 1 June 2017.			
108	NAPROXEN (amended pack size) Tab long-acting 750 mg – <b>1% DV Jun-15 to 2018</b> .....	5.60	28	<b>Naprosyn SR 750</b>
	Tab long-acting 1 g – <b>1% DV Jun-15 to 2018</b> .....	6.53	28	<b>Naprosyn SR 1000</b>
	Note – Naproxen tab 750 mg and 1 g pack size change from 90 pack bottle to 28 blister pack. The 90 tablet packs will be delisted at a later date.			

### NERVOUS SYSTEM

109	<b>BENZTROPINE BENZTROPINE MESYLATE</b> (chemical name change) Tab 2 mg .....	7.99	60	Benztrop
	Inj 1 mg per ml, 2 ml ampoule.....	95.00	5	Cogentin
117	VENLAFAXINE (brand change) Cap 37.5 mg – <b>1% DV Jun-17 to 2020</b> .....	6.38	84	<b>Enlafax XR</b>
	Cap 75 mg – <b>1% DV Jun-17 to 2020</b> .....	8.11	84	<b>Enlafax XR</b>
	Cap 150 mg – <b>1% DV Jun-17 to 2020</b> .....	11.16	84	<b>Enlafax XR</b>
	Note – Arrow-Venlafaxine XR tab modified release 37.5 mg, 75 mg, 150 mg and 225 mg, and Efexor XR cap modified release 37.5 mg, 75 mg and 150 mg to be delisted from 1 June 2017.			
123	APREPITANT (new listing) → Cap 40 mg.....	71.43	5	Emend
123	SUMATRIPTAN (brand change) Tab 50 mg – <b>1% DV Jun-17 to 2019</b> .....	24.44	100	<b>Apo-Sumatriptan</b>
	Tab 100 mg – <b>1% DV Jun-17 to 2019</b> .....	46.23	100	<b>Apo-Sumatriptan</b>
	Note – Arrow-Sumatriptan tab 50 mg and 100 mg to be delisted from 1 June 2017.			
124	GRANISETRON (delisting) Tab 1 mg – <b>1% DV Jan-15 to 2017</b> .....	5.98	50	<b>Granirex</b>
	Note – Granirex tab 1 mg to be delisted from 1 October 2017.			
134	BUPROPION HYDROCHLORIDE (addition of HSS) Tab modified-release 150 mg – <b>1% DV Jun-17 to 2020</b> .....	11.00	30	<b>Zyban</b>

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

**Changes to Section H Part II – effective 1 April 2017 (continued)**

**ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS**

142	ERLOTINIB (amended restriction – amended criteria shown only)		
	→ Tab 100 mg.....	764.00	30 Tarceva
	→ Tab 150 mg.....	1,146.00	30 Tarceva
	Restricted		
	Initiation		
	<i>Re-assessment required after 4 months</i>		
	All of the following:		
	1 Patient has locally advanced or metastatic, unresectable, non-squamous Non-Small Cell Lung Cancer (NSCLC); and		
	2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and		
	3 <b>Either</b> Any of the following:		
	3.1 Patient is treatment naive; or		
	<del>3.2 Both:</del>		
	3.2.1 <del>Patient has documented disease progression following treatment with first line platinum based chemotherapy; and</del>		
	3.2.2 <del>Patient has not received prior treatment with gefitinib; or</del>		
	<del>3.2.3 Both:</del>		
	3.2.1.3.1 The patient has discontinued gefitinib within 12 weeks of starting treatment due to intolerance; and		
	3.2.2.3.2 The cancer did not progress while on gefitinib; and		
	4 Erlotinib is to be given for a maximum of 3 months.		

**SPECIAL FOODS**

211	PROTEIN SUPPLEMENT (delisting)		
	→ Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can		e.g. <i>Promod</i>
	Note – Promod powder to be delisted from 1 April 2017.		
213	AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) (delisting)		
	→ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can		e.g. <i>MSUD Maxamaid</i>
	Note – MSUD Maxamaid to be delisted from 1 May 2017.		

# Index

## Pharmaceuticals and brands

<b>A</b>		
Adalat 10 .....	4	
Alfacalcidol .....	4	
Amino acid formula (without isoleucine, leucine and valine) .....	11	
Aminolevulinic acid hydrochloride .....	6	
Amiodarone hydrochloride.....	9	
Amoxicillin with clavulanic acid .....	4	
Androderm.....	4	
Apo-Leflunomide.....	10	
Apo-Prednisone .....	9	
Apo-Sumatriptan .....	10	
Aprepitant .....	10	
Auranofin .....	10	
Azathioprine .....	7	
<b>B</b>		
Benzatropine mesylate .....	10	
Benztrop .....	10	
Benztropine mesylate .....	10	
Bupropion hydrochloride .....	10	
<b>C</b>		
Calcipotriol.....	7	
Celecoxib .....	5	
Celecoxib Pfizer.....	5	
Clomifene citrate .....	9	
Clomiphene citrate .....	9	
Cogentin .....	10	
Curam .....	4	
<b>D</b>		
Daivonex.....	7	
Darunavir .....	9	
Dexamethasone phosphate.....	7	
Dimethicone.....	4, 7	
<b>E</b>		
Emend .....	10	
Enlifax XR .....	10	
Erlotinib .....	11	
<b>F</b>		
Flamazine.....	4	
Fluphenazine decanoate .....	7	
Fucidin.....	9	
Fusidic acid.....	9	
<b>G</b>		
Gliolan .....	6	
Granirex .....	10	
Granisetron .....	10	
<b>H</b>		
healthE Dimethicone 4% Lotion .....	4, 7	
<b>I</b>		
Imuran.....	7	
Influenza vaccine.....	6, 8	
Influvac.....	6, 8	
<b>L</b>		
Leflunomide .....	10	
Levonorgestrel .....	9	
Lodi .....	9	
<b>M</b>		
Metronidazole .....	7	
Modcate.....	7	
Morphine tartrate.....	5	
MSUD Maxamaid .....	11	
Mylan Clomiphen .....	9	
<b>N</b>		
Naprosyn SR 750.....	10	
Naprosyn SR 1000.....	10	
Naproxen .....	10	
Nifedipine.....	4	
Nilstat .....	4	
Nystatin .....	4	
<b>O</b>		
One-Alpha.....	4	
Orion Temozolomide .....	5	
<b>P</b>		
Pegasys RBV Combination Pack .....	5	
Pegylated interferon alfa-2a .....	5	
Peptide-based enteral feed 1.5 Kcal/ml .....	6	
Piperacillin with tazobactam .....	7	
Postinor-1.....	9	
Prednisone.....	9	
Prezista.....	9	
Promod.....	11	
Protein supplement .....	11	
Pyridoxine hydrochloride .....	4	
<b>S</b>		
Serophene .....	9	
Sodium chloride.....	9	
Sodium cromoglycate .....	7	
Sulphadiazine silver.....	4	
Sumatriptan .....	10	
<b>T</b>		
Tarceva.....	11	
Tazocin EF .....	7	
Temozolomide .....	5	
Testosterone.....	4	
<b>V</b>		
Venlafaxine .....	10	
Vital.....	6	
<b>W</b>		
Water.....	9	
<b>Z</b>		
Zyban .....	10	



**Email:** [enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz)

**www.pharmac.govt.nz/medicines/hospital-pharmaceuticals**

**Pharmaceutical Management Agency**

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand  
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

ISSN 1179-3694 (Print) - ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand